Katharine Morgan, executive vice president, ASTM, and Richard M. Johnson, president, PDA, signed the MOU.

“The MOU between ASTM International and PDA demonstrates ASTM’s flexibility and evolution as a solutions provider,” says Dan Smith, vice president of technical operations at ASTM. “The migration of PDA’s intellectual property into ASTM’s best-in-class development process is a wonderful example of our commitment to cultivate the highest quality technical content into trusted standards of choice worldwide.”

Russell Madsen, president of the Williamsburg Groups, a pharmaceutical consulting organization, has worked with both ASTM and PDA. He says, “The MOU is important because it aligns PDA’s strengths in producing guidance documents and technical reports with the strengths of ASTM, which produces internationally recognized consensus standards. Many of PDA’s technical reports can serve as a basis for ASTM standards, enhancing their value acceptance and regulatory importance.”

Formed in 2003, ASTM Committee E55 on Manufacture of Pharmaceutical Products addresses issues related to process control, design and performance, as well as quality acceptance/assurance tests, for the pharmaceutical manufacturing industry.

PDA, founded in 1946, is the leading global provider of science, technology and regulatory information, as well as education for the pharmaceutical and biopharmaceutical community. To learn more about PDA technical reports, visit www.pda.org.

ASTM welcomes participation in the development of its standards. Become a member at www.astm.org/JOIN.

For more news in this sector, visit www.astm.org/sn-medical.

ASTM Committee E55 on Manufacture of Pharmaceutical Products Next Meeting: April 28-30, 2015, Lisbon, Portugal
Media Inquiries: Nathan Osburn, tel +1.610.832.9603; nosburn@astm.org
ASTM Staff Contact: Christine DeJong, tel +1.610.832.9736; cdejong@astm.org